The team at Pinpoint Patient Recruiting is searching for people diagnosed with metastatic castrate-resistant prostate cancer (mCRPC) to participate in a 60-minute virtual market research opportunity about their experiences. The information gathered will be used to help communication and education materials about mCRPC.

 

Will you qualify?
If you or the person you care for meet the following criteria, you may be eligible to participate:​

• have received a second-generation AR antagonists (such as enzalutamide, darolutamide, abiraterone or apalutamide) as part of mCRPC treatment

If you qualify for and complete the 60-minute virtual interview, you will receive a check for $125 as a thank you for participating. 

To see if you qualify please fill out the form below; a team member will email you within 24-48 hours with additional information about the opportunities. If you have questions about the study please email Ingles Adams at ingles@pinpointpatientrecruiting.com.

​

*Please note, you must be a current resident of the US and 18 or older to qualify for and participate in this study. All information shared with Pinpoint will remain confidential. 

​